Pradaxa Attorneys Discuss Dangers Despite EU Approval
Boehringer Ingelheim announced on June 6th, 2014, that their drug Pradaxa had been approved for use in the European Union (EU). Pradaxa (dabigatran etexilate) is used to treat and prevent deep vein thrombosis (DVT) and pulmonary embolism (PE). The approval paves the way for Pradaxa to spread into the European market, off-setting warfarin and pushing further into public use. Warfarin has been the go to anticoagulant for a number of years.
The Pitfalls Of Pradaxa
The EU’s approval should not stop the discussion of the very serious side effects of Pradaxa. Despite its approval, Pradaxa is still associated with a number of health complications. The blood thinner has been linked to cerebral hemorrhaging, severe bleeding, and gastrointestinal bleeding. Though warfarin has the capacity for similar side effects, it has an injectable counter that immediately reverses the anticoagulant. That allows doctors to get the bleeding of patients taking warfarin under control much more effectively than Pradaxa. Many Pradaxa attorneys allege that their clients were not advised of the lack of a reversible agent for the medication before taking it.
Pradaxa has been through several tests and some of the longest running DVT and PE trials in the market. It does score high marks in safety in several areas. Unfortunately, Pradaxa attorneys have filed many lawsuits on behalf of people injured by this drug because it does not presently have an effective counter, like warfarin. Though it has proven to be quite popular since it was introduced in 2008, the lack of an effective counter is the reason that not all doctors have embraced Pradaxa as a replacement.
Federal lawsuits have been gathered into a MultiDistrict Litigation (MDL). The lawsuits are pending in the United States District Court for the Southern District of Illinois under presiding Judge David Herndon. The MDL is currently in the “discovery” phase. During this period, Boehringer Ingelheim is required to turn over records regarding any health risks they identified related to Pradaxa. Several Boehringer Ingelheim employees and executives will also be questioned as part of the information gathering process.
Judge Herndon released a case management statement announcing the first bellwether trial would begin on September 8th, 2014. Bellwether trials are conducted off of what Pradaxa attorneys feel are the “average” of the overall complaints. It gives the court opportunity to gauge the potential severity of the issue without having to hear thousands of individual cases at once. What does that mean for people harmed by Pradaxa, still sitting on the sidelines? The creation of the MDL sets in motion legal protections for Boehringer Ingelheim. There are now invisible deadlines for filing that relate to circumstances specific to an individual’s case, so call the American Injury Attorney Group today to be connected with Pradaxa attorneys.
The Need for Pradaxa Attorneys
The American Injury Attorney Group is affiliated with experienced Pradaxa attorneys. To be connected with one, call today for a free, no obligation consultation. We can evaluate your case and determine whether you have a claim. If you do, we can connect you with one of our affiliated Pradaxa attorneys for representation. Contact American Injury Attorney Group today for more information.